参考文献/References:
[1] Luis-Rodríguez D, Martínez-Castelao A, Górriz JL, et al. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy[J].World J Diabetes, 2012,3(1):7-18.
[2] Niewczas MA, Ficociello LH, Johnson AC, et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes[J].Clin J Am Soc Nephrol, 2009,4(1):62-70.
[3] Shelbaya S, Amer H, Seddik S, et al. Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients[J].Eur Rev Med Pharmacol Sci, 2012,16(2):176-182.
[4] Rüster C, Bondeva T, Franke S, et al.Angiotensin Ⅱ upregulates RAGE expression on podocytes: role of AT2 receptors[J].Am J Nephrol, 2009,29(6):538-550.
[5] Sanchez-Ni?o MD, Sanz AB, Ihalmo P, et al. The MIF receptor CD74 in diabetic podocyte injury[J].J Am Soc Nephrol, 2009,20(2):353-362.
[6] Lewko B, Stepinski J.Hyperglycemia and mechanical stress: targeting the renal podocyte[J].J Cell Physiol, 2009,221(2):288-295.
[7] Yan SF, Yan SD, Ramasamy R, et al. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation[J].Ann Med, 2009,41(6):408-422.
[8] Ishibashi Y, Matsui T, Takeuchi M, et al. Metformin inhibits advanced glycation end products(AGEs)-induced renal tubular cell injury by suppressing reactive Oxygen species Generation via reducing receptor for AGEs(RAGE)expression[J].Horm Metab Res, 2012,44(12):891-895.
[9] Ramasamy R,Yan SF,Schmidt AM. Receptor for AGE(RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications[J].Ann N Y Acad Sci, 2011,1243:88-102.
[10] Sourris KC, Forbes JM. Interactions between advanced glycation end-products(AGE)and their receptors in the development and progression of diabetic nephropathy- are these receptors valid therapeutic targets[J].Curr Drug Targets, 2009,10(1):42-50.
[11] Louro TM, Matafome PN, Nunes EC, et al. Insulin and metformin May prevent renal injury in young type 2 diabetic Goto-Kakizaki rats[J].Eur J Pharmacol, 2011,653(1/3):89-94.
[12] Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al. Metformin against TGFβ-induced epithelial-to-mesenchymal transition(EMT): from Cancer stem cells to aging-associated fibrosis[J].Cell Cycle, 2010,9(22):4461-4468.
[13] Alhaider AA, Korashy HM, Sayed-Ahmed MM, et al. Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression[J].Chem Biol Interact, 2011,192(3):233-242.
[14] Andrews M, Soto N, Arredondo M. Effect of metformin on the expression of tumor necrosis factor-alpha, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients[J].Rev Med Chil,2012, 140(11): 1377-1382.
[15] Krysiak R, Okopien B. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose[J].Metabolism, 2013,62(1):39-43.
[16] Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation[J].Cell Metab, 2010,11(6):554-565.
[17] Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase[J].J Biol Chem, 2011,286(1):1-11.
[18] 姚烽,汲广岩,张力.腺苷酸活化蛋白激酶:炎症调控新靶点[J].生理学报, 2012,64(3):341-345.
[19] Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells[J].Arterioscler Thromb Vasc Biol, 2006,26(3):611-617.
[20] Hattori Y, Suzuki K, Hattori S, et al. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells[J].Hypertension, 2006,47(6):1183-1188.
[21] Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview[J].Clin Sci(Lond), 2012,122(6):253-270.
[22] Morales AI, Detaille D, Prieto M, et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway[J].Kidney Int, 2010,77(10):861-869.
[23] Piwkowska A, Rogacka D, Jankowski M, et al. Metformin induces suppression of NAD(P)H oxidase activity in podocytes[J].Biochem Biophys Res Commun, 2010,393(2):268-273.
[24] Ishibashi Y, Matsui T, Takeuchi M, et al. Beneficial effects of metformin and irbesartan on advanced glycation end products(AGEs)-RAGE-induced proximal tubular cell injury[J].Pharmacol Res, 2012,65(3):297-302.
[25] Alhaider AA, Korashy HM, Sayed-Ahmed MM, et al. Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression[J].Chem Biol Interact, 2011,192(3):233-242.
[26] Mao XM, Liu H, Tao XJ, et al. Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes[J].Diabetes Metab Res Rev, 2009,25(5):435-441.
相似文献/References:
[1]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[2]李雅,王志斌,刘玮晔,等.巨噬细胞与糖尿病肾病[J].国际内分泌代谢杂志,2014,(06):393.[doi:10.3760/cma.j.issn.1673-4157.2014.06.009]
Li Ya*,Wang Zhibin,Liu Weiye,et al.Macrophages and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(05):393.[doi:10.3760/cma.j.issn.1673-4157.2014.06.009]
[3]王丹,关美萍,薛耀明.早期生长反应因子-1与糖尿病肾病[J].国际内分泌代谢杂志,2014,(06):397.[doi:10.3760/cma.j.issn.1673-4157.2014.06.010]
Wang Dan,Guan Meiping,Xue Yaoming..Early growth response factor-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(05):397.[doi:10.3760/cma.j.issn.1673-4157.2014.06.010]
[4]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(05):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
[5]杨健姝,华飞,唐暎,等.二甲双胍在多囊卵巢综合征患者妊娠期的应用[J].国际内分泌代谢杂志,2014,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
Yang Jianshu,Hua Fei,Tang Ying,et al.The application of metformin in the pregnant patients with polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2014,(05):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
[6]玄先法,李清芹,王玉新,等.肾炎康复片联合缬沙坦治疗Ⅳ期糖尿病肾病蛋白尿的临床研究[J].国际内分泌代谢杂志,2014,(05):353.[doi:10.3760/cma.j.issn.1673-4157.2014.05.019]
Xuan Xianfa,Li Qingqin,Wang Yuxin,et al.Clinical study of Shenyankangfu tablet combined with valsartan capsule on proteinuria in patients with stage Ⅳ diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(05):353.[doi:10.3760/cma.j.issn.1673-4157.2014.05.019]
[7]曹萌 陈堃 茅晓东 刘超.限食治疗糖尿病肾病的研究进展[J].国际内分泌代谢杂志,2015,(06):395.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.009]
Cao Meng,Chen Kun,Mao Xiaodong,et al.Effects of diet restriction on diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):395.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.009]
[8]于菁 王秋月.多聚ADP核糖聚合酶-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(06):409.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.013]
Yu Jing,Wang Qiuyue..Poly(ADP-ribose)polymerase-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):409.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.013]
[9]马静茹,牟新.表观遗传学与糖尿病肾病[J].国际内分泌代谢杂志,2016,36(01):52.[doi:10.3760/cma.j.issn.1673-4157.2016.01.013]
Ma Jingru*,Mou Xin..Epigenetics and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(05):52.[doi:10.3760/cma.j.issn.1673-4157.2016.01.013]
[10]杨薇,李春君,孙蓓,等.雷公藤多苷对糖尿病肾病大鼠核因子-κB
信号通路的影响[J].国际内分泌代谢杂志,2016,36(02):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
Yang Wei*,Li Chunjun,Sun Bei,et al.Effects of triperygium wilfordii polyglucoside on nuclear factor-κB signaling pathway in rats with diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(05):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
[11]林杨 叶山东.二甲双胍对糖尿病肾病保护作用的机制[J].国际内分泌代谢杂志,2018,38(01):52.[doi:10.3760/cma.j.issn.1673-4157.2018.01.014]
Lin Yang*,Ye Shandong. *.Protective effects of metformin on diabetic nephropathy and its mechanism[J].International Journal of Endocrinology and Metabolism,2018,38(05):52.[doi:10.3760/cma.j.issn.1673-4157.2018.01.014]